{
    "ticker": "GERN",
    "name": "Geron Corporation",
    "description": "Geron Corporation is a clinical-stage biopharmaceutical company focused on the development of novel cancer therapies. Founded in 1990 and headquartered in Menlo Park, California, Geron is dedicated to advancing its lead product candidate, imetelstat, a telomerase inhibitor that has shown promise in treating hematologic malignancies. The company's innovative approach targets cancer stem cells in various forms of cancer, potentially providing a new avenue for treatment where traditional therapies have failed. Geron's research and development efforts are primarily centered around imetelstat, which is currently being evaluated in clinical trials for conditions like myelofibrosis and essential thrombocythemia. Leveraging a robust intellectual property portfolio, Geron aims to bring transformative treatments to patients with significant unmet medical needs. The company collaborates with leading research institutions and has partnerships with other biopharmaceutical firms to enhance its development capabilities. With a commitment to scientific excellence and patient-centric solutions, Geron is at the forefront of cancer research and strives to make a meaningful impact on the lives of cancer patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Menlo Park, California, USA",
    "founded": "1990",
    "website": "https://www.geron.com",
    "ceo": "John A. Scarlett",
    "social_media": {
        "twitter": "https://twitter.com/GeronCorp",
        "linkedin": "https://www.linkedin.com/company/geron-corporation/"
    },
    "investor_relations": "https://investors.geron.com",
    "key_executives": [
        {
            "name": "John A. Scarlett",
            "position": "CEO"
        },
        {
            "name": "Lynn Seely",
            "position": "CMO"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Therapeutics",
            "products": [
                "Imetelstat"
            ]
        }
    ],
    "seo": {
        "meta_title": "Geron Corporation | Innovative Cancer Therapies",
        "meta_description": "Learn about Geron Corporation, a leader in cancer research and development. Explore our innovative therapies and commitment to improving patient outcomes.",
        "keywords": [
            "Geron",
            "Imetelstat",
            "Cancer Therapy",
            "Biotechnology",
            "Hematologic Malignancies"
        ]
    },
    "faq": [
        {
            "question": "What is Geron known for?",
            "answer": "Geron is known for its development of imetelstat, a telomerase inhibitor for cancer treatment."
        },
        {
            "question": "Who is the CEO of Geron?",
            "answer": "John A. Scarlett is the CEO of Geron Corporation."
        },
        {
            "question": "Where is Geron headquartered?",
            "answer": "Geron is headquartered in Menlo Park, California, USA."
        },
        {
            "question": "What is Geron's main product?",
            "answer": "Geron's main product is imetelstat, which is currently in clinical trials for various hematologic malignancies."
        },
        {
            "question": "When was Geron founded?",
            "answer": "Geron was founded in 1990."
        }
    ],
    "competitors": [
        "AZN",
        "BMY",
        "MRNA",
        "CLVS"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "ABBV",
        "JNJ"
    ]
}